Synthorx

Synthorx

Synthorx

With synthetic DNA nucleotides, X and Y, Synthorx is a synthetic biology company, synthesizing solutions for drug discovery, diagnostics and vaccines.
Founded
2014
Raised
$79M
Follow us
Alexa global traffic share
Twitter followers
Acquired by
Sanofi
03 Dec 2019
Latest funding Show all
$10,000,000
Venture capital (Series B) - 2016
Avalon Ventures Correlation Ventures RA Capital Management
Xconomy

Synthorx’s Shawver Joins Silverback Therapeutics as New Top Exec

FinSMEs

Sanofi Closes Purchase of Synthorx

Xconomy

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx

$63,000,000 Venture capital (Series C)
Venture Funding News , PE HUB , Xconomy

Synthorx Announces $63M Series C Funding

FinSMEs

Synthorx Raises $63M in Series C Financing

Funding Science
$10,000,000 Venture capital (Series B)
FinSMEs , Xconomy

Synthorx Completes $10M Series B Financing

Funding Science
Xconomy

Synthorx Makes Proteins Using Expanded Alphabet of Synthetic DNA

Science